BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Salazar G. Depression and IBD. J Pediatr Gastroenterol Nutr 2014;58:543-4. [PMID: 24509306 DOI: 10.1097/MPG.0000000000000332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2927-36. [PMID: 23867874 DOI: 10.1097/MIB.0b013e31829aad16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
3 . Bibliography. Current world literature. Neuro opthalmology. Curr Opin Ophthalmol 2008;19:541-4. [PMID: 18854700 DOI: 10.1097/ICU.0b013e328317c7c4] [Reference Citation Analysis]
4 Baddley J, Cantini F, Goletti D, Gómez-reino J, Mylonakis E, San-juan R, Fernández-ruiz M, Torre-cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clinical Microbiology and Infection 2018;24:S10-20. [DOI: 10.1016/j.cmi.2017.12.025] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 20.5] [Reference Citation Analysis]
5 Bradley GM, Oliva-hemker M. Infliximab for the treatment of pediatric ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;6:659-65. [DOI: 10.1586/egh.12.53] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 . Bibliography. Current world literature. Systemic lupus erythematosus and Sjögren's syndrome. Curr Opin Rheumatol 2008;20:631-2. [PMID: 18698190 DOI: 10.1097/BOR.0b013e3283110091] [Reference Citation Analysis]
7 Shirley D, Stephens I. PRIMARY TREATMENT OF INCOMPLETE KAWASAKI DISEASE WITH INFLIXIMAB AND METHYLPREDNISOLONE IN A PATIENT WITH A CONTRAINDICATION TO INTRAVENOUS IMMUNE GLOBULIN. Pediatric Infectious Disease Journal 2010;29:978-9. [DOI: 10.1097/inf.0b013e3181e05564] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
8 Bradley GM, Oliva-Hemker M. Pediatric ulcerative colitis: current treatment approaches including role of infliximab. Biologics 2012;6:125-34. [PMID: 22740771 DOI: 10.2147/BTT.S31833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
9 Olbjørn C, Nakstad B, Småstuen MC, Thiis-evensen E, Vatn MH, Perminow G. Early anti-TNF treatment in pediatric Crohn’s disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients. Scandinavian Journal of Gastroenterology 2014;49:1425-31. [DOI: 10.3109/00365521.2014.966316] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
10 Cucchiara S, Escher JC, Hildebrand H, Amil-dias J, Stronati L, Ruemmele FM. Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies? Journal of Pediatric Gastroenterology & Nutrition 2009;48:257-67. [DOI: 10.1097/mpg.0b013e31818cf555] [Cited by in Crossref: 33] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Gumbs AA, Zain J, O’connor OA. Importance of Early Splenectomy in Patients with Hepatosplenic T-Cell Lymphoma and Severe Thrombocytopenia. Ann Surg Oncol 2009;16:2014-7. [DOI: 10.1245/s10434-009-0470-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
12 Béres NJ, Kiss Z, Sztupinszki Z, Lendvai G, Arató A, Sziksz E, Vannay Á, Szabó AJ, Müller KE, Cseh Á, Boros K, Veres G. Altered mucosal expression of microRNAs in pediatric patients with inflammatory bowel disease. Dig Liver Dis 2017;49:378-87. [PMID: 28077249 DOI: 10.1016/j.dld.2016.12.022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
13 Veres G, Baldassano RN, Mamula P. Infliximab therapy for pediatric Crohn's disease. Expert Opinion on Biological Therapy 2007;7:1869-80. [DOI: 10.1517/14712598.7.12.1869] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
14 Cseh A, Vasarhelyi B, Molnar K, Szalay B, Svec P, Treszl A, Dezsofi A, Lakatos PL, Arato A, Tulassay T, Veres G. Immune phenotype in children with therapy-naïve remitted and relapsed Crohn’s disease. World J Gastroenterol 2010; 16(47): 6001-6009 [PMID: 21157977 DOI: 10.3748/wjg.v16.i47.6001] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 McCluggage LK. Safety of TNF inhibitors in adolescents and children. Adolesc Health Med Ther 2011;2:1-8. [PMID: 24600270 DOI: 10.2147/AHMT.S8163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Béres NJ, Szabó D, Kocsis D, Szűcs D, Kiss Z, Müller KE, Lendvai G, Kiss A, Arató A, Sziksz E, Vannay Á, Szabó AJ, Veres G. Role of Altered Expression of miR-146a, miR-155, and miR-122 in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:327-35. [PMID: 26752469 DOI: 10.1097/MIB.0000000000000687] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
17 Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol. 2009;6:92-106. [PMID: 19153563 DOI: 10.1038/ncpgasthep1340] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 5.2] [Reference Citation Analysis]
18 Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24 Suppl 1:3-14. [PMID: 21175228 DOI: 10.2165/11586290-000000000-00000] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
19 Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther 2015;6:79-85. [PMID: 29388577 DOI: 10.2147/PHMT.S64943] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 de Zoeten E, Mamula P. What are the guidelines for using biologics in pediatric patients?: . Inflammatory Bowel Diseases 2008;14:S259-61. [DOI: 10.1097/00054725-200810001-00122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Pozadzides JV, Pro B. Hepatosplenic T-cell lymphoma and TNF-α inhibitors. Expert Rev Hematol 2009;2:611-4. [PMID: 21082951 DOI: 10.1586/ehm.09.62] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
22 DeBoer MD, Barnes BH, Stygles NA, Sutphen JL, Borowitz SM. Changes in inflammation and QoL after a single dose of infliximab during ongoing IBD treatment. J Pediatr Gastroenterol Nutr. 2012;54:486-490. [PMID: 21946833 DOI: 10.1097/mpg.0b013e3182382ee3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
23 Veres G, Putz R, Szabó D, Molnár K, Bodánszky H, Dezsofi A, Arató A. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn’s disease]. Orv Hetil. 2009;150:1858-1860. [PMID: 19789146 DOI: 10.1556/oh.2009.28731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214-223; quiz 224. [PMID: 21157441 DOI: 10.1038/ajg.2010.464] [Cited by in Crossref: 146] [Cited by in F6Publishing: 117] [Article Influence: 12.2] [Reference Citation Analysis]
25 Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19-30. [PMID: 17944997 DOI: 10.1111/j.1365-2036.2007.03553.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 4.6] [Reference Citation Analysis]
26 Veres G, Szabó D, Várkonyi Á, Tari B, Polgár M, B. Kovács J, Horváth Á, Tomsits E, Tokodi I, Bodánszky H, Dezsőfi A, Szakos E, Vass N, Ruszinkó V, Kovács M, Müller KE, Arató A. Analysis of infliximab treated pediatric patients with Crohn disease in Hungary. Orvosi Hetilap 2010;151:179-83. [DOI: 10.1556/oh.2010.28792] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]